Aspirin for primary prevention of cardiovascular disease.

Flavonolignans inhibit the arachidonic acid pathway in blood platelets. BMC Complement Altern Med (2017) 0.76

Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound. Evid Based Complement Alternat Med (2016) 0.76

Higher rate of microscopic hematuria in elderly patients who take regular doses of aspirin: Result from AHAP Study. Caspian J Intern Med (2016) 0.75

Evaluation on antithrombotic effect of aspirin eugenol ester from the view of platelet aggregation, hemorheology, TXB2/6-keto-PGF1α and blood biochemistry in rat model. BMC Vet Res (2016) 0.75

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 50.94

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 20.22

High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med (2006) 14.79

Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J (2012) 13.74

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation (2002) 9.04

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90

Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA (2008) 7.84

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ (2008) 7.47

Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42

Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med (2005) 6.39

Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet (2001) 6.38

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA (2008) 6.15

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA (2006) 5.95

Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J (1985) 5.83

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 5.65

Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol (2011) 5.46

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA (1998) 5.37

Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA (2010) 5.10

Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med (1984) 5.02

Association of aspirin use with major bleeding in patients with and without diabetes. JAMA (2012) 4.94

Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA (2014) 4.85

Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation (1993) 4.75

Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57

Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ (1995) 4.50

The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ (2007) 4.48

Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol (2012) 3.49

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA (2007) 3.28

Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med (2011) 2.65

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA (1992) 2.52

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50

Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation (1985) 2.46

Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke (2005) 2.41

The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med (2010) 2.30

Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ (2011) 2.10

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA (2010) 1.97

Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes (2014) 1.71

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation (2010) 1.69

Sharing the care to improve access to primary care. N Engl J Med (2012) 1.49

Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.46

The discovery of aspirin's antithrombotic effects. Tex Heart Inst J (2007) 1.45

Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J (2010) 1.39

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J (2011) 1.35

Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation (2012) 1.34

Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil (2009) 1.28

Interplay of coronary artery calcification and traditional risk factors for the prediction of all-cause mortality in asymptomatic individuals. Circ Cardiovasc Imaging (2012) 1.22

Gaps in capacity in primary care in low-resource settings for implementation of essential noncommunicable disease interventions. Int J Hypertens (2012) 1.20

Electronic health record-based patient identification and individualized mailed outreach for primary cardiovascular disease prevention: a cluster randomized trial. J Gen Intern Med (2012) 1.13

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess (2013) 1.11

Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of Cameroon. PLoS One (2014) 1.11

Don't use aspirin for primary prevention of cardiovascular disease. BMJ (2010) 1.09

Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep (2014) 1.08

Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med (2011) 1.05

Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol (2014) 1.05

Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J (2012) 1.04

Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One (2013) 1.03

Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol (2006) 1.01

TGF-beta1: a novel target for cardiovascular pharmacology. Cytokine Growth Factor Rev (2007) 0.99

Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol (2011) 0.98

Acetylsalicylic acid inhibits cell proliferation by involving transforming growth factor-beta. Circulation (2003) 0.97

Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease? J Gen Intern Med (2015) 0.95

Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation (1993) 0.91

Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction. Am Heart J (2012) 0.91

The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines Executive Summary. Can J Cardiol (2011) 0.88

Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study. Circ Cardiovasc Qual Outcomes (2013) 0.84

Aspirin: its risks, benefits, and optimal use in preventing cardiovascular events. Cleve Clin J Med (2013) 0.83

Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med (2011) 0.83

Is aspirin useful in primary prevention? Eur Heart J (2013) 0.80

Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study. Acta Diabetol (2014) 0.79

Proton pump inhibitors and hospital discharge rates for gastrointestinal events in Italy: a national ecological study. Clin Ther (2007) 0.78

Prevention: Aspirin in primary prevention needs individual judgements. Nat Rev Cardiol (2014) 0.78

Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? Vasc Health Risk Manag (2015) 0.76